12 live debatesLast scanned Sep 17, 2026, 8:41 AM UTC
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.0 · 40%
How much practice changes9.0 · 30%
How much is genuinely new8.5 · 20%
Clinician attention8.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.7 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 97%.
Heat is an AI estimate, not a vote. 1 cardiologist has voted so far; the measured split publishes at 10 and then replaces this estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Values & turf — what this means
A trade-off or turf question that more data alone won't settle — it turns on risk tolerance, cost, or which specialty owns the decision.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (5 vs 1 here). The bar shows how that lean divides between the two camps — the grey middle is the 3 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (24 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Aug 2024).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
01★ Top debateField-wide debate
One BP target for all, or tailor it?
2025 AHA/ACC hypertension guideline: lower thresholds or individualized targets?
How you read the new guideline decides whether every hypertensive patient gets pushed to under 130/80, or whether frail and elderly patients get looser goals to avoid falls, kidney injury, and overtreatment.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.0 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.3 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.8 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.0 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.0 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.5 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.8 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.5 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.0 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.5 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.5 · 40%
Debates are surfaced by a continuous scan of the cardiology literature and the conversation among clinicians. The heat score (0-10) reflects how live and consequential the disagreement is right now and drives the ranking; it becomes the measured expert split as cardiologists weigh in. Quotes and engagement counts are scan-reported and link to their primary source.
For adults with confirmed hypertension under the 2025 guideline, should clinicians drive all patients toward <130/80, or set individualized targets by frailty and risk?
Push everyone to <130/80
A single low, clear target is easy to act on and drives down strokes and heart attacks across the whole population, where undertreatment is the bigger real-world problem.
“Based on these, the 2025 American College of Cardiology/American Heart Association guideline recommends in adults with confirmed hypertension, an office blood pressure goal of <130/80 mm Hg, with encouragement to further reduce systolic blood pressure to <120 mm Hg. Here, we set ”
Lucas Lauder · Cardiologist; co-author of debate article supporting 2025 guideline targets · Hypertension ↗
“Based on these, the 2025 American College of Cardiology/American Heart Association guideline recommends in adults with confirmed hypertension, an office blood pressure goal of <130/80 mm Hg, with encouragement to further reduce systolic blood pressure to <120 mm Hg.”
Felix Mahfoud · Interventional cardiologist; co-author of debate article supporting lower targets · Hypertension ↗
“Debate on the 2025 Guideline... New Blood Pressure Targets, Lower Is Better—And Possible”
“We're trying to get a clear message to primary care clinicians... to encourage them to be more aggressive in managing blood pressure, to get blood pressure lower.”
A rigid low goal risks harming the old, frail, and multimorbid, so targets should flex to individual risk and tolerance rather than one number for all.
“By addressing individual risks earlier and offering more tailored strategies across the lifespan, the 2025 guideline aims to aid clinicians in helping more people manage their blood pressure and reduce the toll of heart disease, kidney disease, Type 2 diabetes and dementia.”
Who: Adults with office BP 130–139/80–89 without established CVD, especially lower-risk primary prevention·24 sources
On the board:since Jun 24, 2026 (2 mo)— time live on Synapse
Patients affected:Millions of patients· hypertension is routine across cardiology
›The evidence
What we know
✓The 2025 AHA/ACC guideline sets an office goal of under 130/80.
✓Lower blood pressure reduces cardiovascular events in most adults.
✓The guideline also stresses risk-based, earlier, and team-based management.
✓Aggressive lowering carries real harms in some patients — falls, kidney injury, dizziness.
What's still unknown
?Whether the same low target truly benefits the very elderly and frail.
?How to identify which patients are helped versus harmed by intensive lowering.
?Long-term outcomes of applying one target across all risk levels in routine practice.
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
How much practice changes9.0 · 30%
How much is genuinely new8.8 · 20%
Clinician attention8.0 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.8 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
Heat is an AI estimate, not a vote. 1 cardiologist has voted so far; the measured split publishes at 10 and then replaces this estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Coordination gap — what this means
The answer is roughly known, but everyday practice and guidelines lag behind the evidence. The fight is about adoption, not the science.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (7 vs 2 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (24 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Aug 2025).
On the boardhow long the question has been live on Synapse (4 weeks).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
02Field-wide debate
Test every adult once for Lp(a)?
Should every adult get a one-time Lp(a) test?
A Class I nudge to test every adult turns a rarely ordered blood test into routine care — and commits millions of people to a lifelong high-risk label that, for now, buys them harder statin and PCSK9 therapy rather than any drug aimed at Lp(a) itself.
Outlook: Evidence is largely in — the gap now is putting it into practice
With no outcome-proven Lp(a)-lowering drug available, should Lp(a) be measured once in every adult — including those with average LDL and no known heart disease — or only in patients where the result would change management today?
Test everyone now
Lp(a) is inherited, causal, and invisible on a standard lipid panel, and a single cheap test reliably finds people whose risk justifies pushing LDL much lower, adding a PCSK9 inhibitor, and screening the family — actions we already know help.
Ann Marie Navar · Writing committee member; prevention cardiologist · HCPLive ↗François Mach · ESC/EAS dyslipidaemia guideline lead · EAS ↗
How much practice changes8.0 · 30%
How much is genuinely new8.2 · 20%
Clinician attention8.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.4 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 97%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (13 vs 1 here). The bar shows how that lean divides between the two camps — the grey middle is the 7 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (38 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Jul 2022).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
03Field-wide debate
Treat high Lp(a) now, or wait for the trials?
Should we measure and treat elevated Lp(a) now or wait for phase 3 outcomes?
Whether we start measuring Lp(a) in everyone and acting on it today, or hold off until 2026 trials tell us if lowering it actually prevents heart attacks.
In patients found to have elevated Lp(a), should we screen broadly and act now — or defer routine measurement and any Lp(a)-targeted treatment until the 2026 outcomes trials report?
Screen and act now
Lp(a) is genetic, lifelong, and identifies high-risk patients we can already help — measure it now and intensify everything else we know works while waiting for the targeted drugs.
“Novel therapeutic approaches show promise for targeted reduction of Lp(a)”
“We want clinicians to start assessing Lp(a) now so that when Lp(a)-targeted therapies become available, we’ll be ready to treat the patients who need them.”
·
How much practice changes7.0 · 30%
How much is genuinely new7.3 · 20%
Clinician attention8.0 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.0 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 86%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (6 vs 3 here). The bar shows how that lean divides between the two camps — the grey middle is the 8 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (26 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Jan 2025).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
04Field-wide debate
Do the new ACS guidelines contradict themselves?
Gray areas in 2025 ACC/AHA ACS guidelines: what to do with conflicting recommendations?
How cardiologists read the fine print of one guideline decides whether millions of heart attack patients get a year of dual antiplatelet therapy or an early de-escalation — and which P2Y12 drug they walk out on.
For ACS patients undergoing PCI under the 2025 ACC/AHA guideline, should the competing Class 1 antiplatelet recommendations be treated as needing formal clarification before they guide care, or as intended flexibility to individualize therapy?
Fix the conflicts first
The guideline carries competing Class 1 recommendations — a full year of dual antiplatelet therapy to cut ischemic events alongside shortening or de-escalating it to cut bleeding — and clinicians can't apply both, so the document needs clarification before it drives practice.
“The 2025 ACC/AHA ACS guidelines remain an area that's still controversial.”
Weighted (40 / 30 / 20 / 10) into the 8.4 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 94%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Coordination gap — what this means
The answer is roughly known, but everyday practice and guidelines lag behind the evidence. The fight is about adoption, not the science.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (11 vs 1 here). The bar shows how that lean divides between the two camps — the grey middle is the 53 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (87 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Apr 2024).
On the boardhow long the question has been live on Synapse (3 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
05Field-wide debate
Role of CAC scoring in intermediate-risk patients per 2026 ACC/AHA dyslipidemia guideline
Get the thresholds wrong and millions of low-risk adults start lifelong statins they may never have needed — or get them right and you finally catch the patients who slip through current risk scores.
Outlook: Evidence is largely in — the gap now is putting it into practice
In borderline/intermediate-risk primary prevention adults, should PREVENT-driven lower thresholds and universal Lp(a) testing trigger statin therapy now, or should CAC scoring be required to confirm risk before treating?
Appropriately intensifies prevention
Lower thresholds plus once-in-a-lifetime Lp(a) testing catch high-risk people that older risk equations miss, and starting statins earlier in the right patients prevents events decades down the line.
“The guideline supports Lp(a) measurement at least once in all adults to refine ASCVD risk assessment.”
Robert S. Blumenthal · Guideline writing committee chair · JACC ↗
“There is indeed overwhelming evidence supporting our practice-changing Guideline.”
Roger S. Blumenthal · Guideline writing committee chair ·
How much practice changes8.5 · 30%
How much is genuinely new6.3 · 20%
Clinician attention8.7 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.8 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 92%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (6 vs 1 here). The bar shows how that lean divides between the two camps — the grey middle is the 2 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (8 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Sep 2024).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
06Specialist debate
Pull beta-blockers a year after MI?
Stop beta-blockers after 1 year in stable post-MI patients with preserved EF?
Millions of stable heart attack survivors take a beta-blocker for life out of habit, and this decides whether stopping is safe or a needless gamble.
In stable post-MI patients with LVEF >=40%, no heart failure, and >=1 year on beta-blockers, should clinicians actively discontinue therapy given the conflicting recent trial evidence?
Stop the drug
Multiple recent trials show no benefit of long-term beta-blockers once the heart pumps normally, so continuing just adds side effects, cost, and pills for no gain.
“Taking stabilized patients off long-term beta-blocker therapy after MI without evidence of heart failure or left ventricular dysfunction does not result in any adverse clinical consequences.”
“Based on the REDUCE-AMI trial results, I would recommend that routine beta-blockers for patients like those included in that trial (revascularized 1- or 2-vessel disease and LVEF ≥50%) is no longer necessary.”
·
How much practice changes8.0 · 30%
How much is genuinely new9.4 · 20%
Clinician attention9.0 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.3 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (8 vs 2 here). The bar shows how that lean divides between the two camps — the grey middle is the 9 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (29 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Oct 2024).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
07Field-wide debate
Bust the clot or just anticoagulate in submassive PE?
Thrombolysis or anticoagulation alone for intermediate-risk PE?
Resolve this and you decide whether thousands of stable PE patients with a strained right ventricle get an invasive clot-busting procedure with bleeding risk, or just blood thinners and watchful waiting.
For intermediate-to-high-risk PE with RV strain and positive troponin but stable hemodynamics, should clinicians use early catheter-directed thrombolysis or reserve it and start with anticoagulation alone?
Intervene early
Catheter-directed thrombolysis unloads the strained right ventricle faster and may cut the chance a stable patient suddenly crashes, instead of waiting for deterioration that's hard to reverse.
“ultrasound-facilitated catheter-directed fibrinolysis plus anticoagulation led to a lower risk”
“61% lower risk of decompensation and other hard outcomes at 7 days”
Stavros V. Konstantinides ·
How much practice changes8.5 · 30%
How much is genuinely new7.9 · 20%
Clinician attention8.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.0 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 92%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (5 vs 1 here). The bar shows how that lean divides between the two camps — the grey middle is the 2 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (18 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Sep 2024).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
08Specialist debate
New AF ablation tech: worth it if efficacy ties?
PFA vs thermal ablation for AF: does it change long-term outcomes?
If pulsed field ablation only matches radiofrequency on keeping AF away, cath labs are switching to a pricier tool for speed and safety alone — and paying for it across nearly every AF ablation.
In paroxysmal AF ablation, when PFA and RF show comparable efficacy, should PFA's safety and speed advantages justify switching from RF as the default?
Adopt PFA now
Even with equal efficacy, PFA spares the esophagus, phrenic nerve, and other collateral tissue and runs faster, so the safety and workflow gains justify the switch.
“Taken together, these data demonstrate that the favorable outcomes of PFA are maintained over the course of 4 years. Coupled with the safety advantages of PFA over thermal ablation, these long-term data support widespread adoption of PFA for the treatment of AF.”
“Both PFA and RFA using the CLOSE protocol showed excellent and similar efficacy. Single-procedure success rates were comparable, although there appeared to be fewer complications and a shorter procedure time with PFA.”
·
How much practice changes8.0 · 30%
How much is genuinely new8.2 · 20%
Clinician attention8.0 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.0 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 97%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (1 vs 4 here). The bar shows how that lean divides between the two camps — the grey middle is the 10 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (42 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Apr 2024).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
09Field-wide debate
Drop aspirin one month after a heart attack?
Default 12-month DAPT in ACS or shorter duration in lower-risk patients?
Nearly every patient stented for a heart attack now faces a choice at one month: stay on two blood thinners for a year and accept the bleeds, or drop aspirin early and trust that clots won't come back.
In patients who have tolerated one month of dual antiplatelet therapy after PCI for acute coronary syndrome, should ticagrelor monotherapy be the default next step, or should 12 months of dual therapy remain the default outside of high bleeding risk?
Drop aspirin at one month
Pooled patient-level data from the ticagrelor-monotherapy trials show clearly less bleeding with no signal of more heart attacks or stent thrombosis, and bleeding after a stent carries its own mortality — so the year of aspirin is a habit, not a requirement, in patients who look stable at 30 days.
“The guidelines are based on an insufficient evidence base.”
Gregg Stone · Interventional cardiologist · TCTMD ↗
Twelve months stays the default
The monotherapy trials were mostly noninferiority designs, heavily enrolled in East Asia, and thin on STEMI and complex anatomy — so calling one month enough for everyone stretches the data past what it can carry, and a missed stent thrombosis is not a nuisance bleed.
How much practice changes8.5 · 30%
How much is genuinely new8.8 · 20%
Clinician attention8.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.2 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 97%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Values & turf — what this means
A trade-off or turf question that more data alone won't settle — it turns on risk tolerance, cost, or which specialty owns the decision.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (9 vs 3 here). The bar shows how that lean divides between the two camps — the grey middle is the 24 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (42 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Jan 2024).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
10Field-wide debate
Replace the valve before symptoms hit?
TAVR for asymptomatic severe aortic stenosis or watchful waiting?
Get this wrong and patients with no symptoms get a valve they didn't need yet — or wait until the heart is already damaged.
Outlook: A judgment call — more data alone won't fully settle it
In asymptomatic severe aortic stenosis, should we offer TAVR now or continue surveillance, given trial endpoints and durability data remain contested?
Fix it early
Waiting for symptoms risks irreversible heart damage and sudden death, and trials show early valve replacement cuts later hospitalizations and unplanned procedures with no clear downside.
“Aligning TAVR coverage with approved FDA indications, including asymptomatic AS”
“With no demonstrated clinical penalty for TAVR, these trial results strongly support a change to the practice and current guidelines for the treatment of aortic stenosis patients.”
Philippe Généreux, MD · Interventional cardiologist ·
How much practice changes9.0 · 30%
How much is genuinely new8.8 · 20%
Clinician attention9.0 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.4 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (7 vs 4 here). The bar shows how that lean divides between the two camps — the grey middle is the 9 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (38 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Sep 2019).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
11Field-wide debate
Drop aspirin early after a heart attack?
Shorter DAPT or earlier aspirin withdrawal after ACS?
Cut aspirin too soon and high-risk patients throw clots; keep it too long and they bleed — this decides the default regimen for nearly everyone leaving the cath lab after ACS.
In post-ACS patients on dual antiplatelet therapy, should aspirin be withdrawn at 1-3 months in favor of P2Y12 monotherapy, or should the standard 12-month regimen continue until powered trials identify who can safely de-escalate?
De-escalate early
Pulling aspirin at 1-3 months and running P2Y12 monotherapy cuts bleeding without a clear ischemic penalty, so the old 12-month dual regimen overtreats most patients.
“antiplatelet and anticoagulation trials test earlier withdrawal of aspirin or oral anticoagulants to reduce bleeding risk”
“test earlier withdrawal of aspirin or oral anticoagulants to reduce bleeding risk and simplify treatment”
Professor Tomasz Guzik ·
How much practice changes8.0 · 30%
How much is genuinely new7.6 · 20%
Clinician attention7.6 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.5 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 100%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (9 vs 1 here). The bar shows how that lean divides between the two camps — the grey middle is the 8 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (39 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Sep 2021).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
12Field-wide debate
Start SGLT2 inhibitors before discharge, or wait?
SGLT2 inhibitors in hospitalized acute heart failure: start now or wait?
If in-hospital initiation wins, millions admitted for heart failure leave on a fourth drug days sooner; if it doesn't, we're loading sick, unstable patients early for no proven added benefit.
In patients hospitalized for acute heart failure, should an SGLT2 inhibitor be started before discharge rather than at the first outpatient visit?
Start before discharge
These drugs work fast and are safe even in decompensated patients, and starting in the hospital is the surest way to make sure the dose actually gets prescribed and taken.
“The totality of randomized trial data really suggests that starting SGLT2 inhibitors during heart failure hospitalization reduces the early risk of cardiovascular death or worsening heart failure and all-cause mortality in the early postdischarge period.”
“The totality of evidence indicates that the therapy is safe and effective across the spectrum of heart failure, including when initiated during hospitalization, and the clinicians should not be dissuaded [from starting] SGLT2 therapy in hospitalized patients when the patient is s”
Insufficient evidence (1 studies, 26700 patients) to determine the effect of intensive blood pressure (bp) management targeting <130/80 mm hg on the outcome in Hypertensive disease.
Dissenting
−Cardiovascular Health Change Patterns After Multifaceted Antihypertensive Intervention and Cardiovascular Outcomes
“There are three drugs that specifically lower Lp(a) that are in Phase III testing right now. Everybody's getting excited about them, but we must wait on the results.”
Karol Watson · Preventive cardiologist · UCLA Health ↗
“We can't treat the Lp(a), but we can treat everything else, and that's an important component of why we think it ought to be measured in everybody.”
Steven Nissen · Preventive cardiologist · Healio ↗
“We should be doing universal screening. It's really just a blood test.”
“The theme here is to modify what you can modify until we have more directed therapy with good clinical trial outcomes.”
Nishant P. Shah · Cardiometabolic specialist · Medscape ↗
“Elevated Lp(a) is a causal risk factor for heart attack, stroke and calcific aortic stenosis, but the percentage of testing in America is around 1%, which is dismal.”
Calling universal testing Class I promises that testing everyone makes people healthier, but no trial has shown that an Lp(a)-guided strategy changes outcomes, and the honest answer for most patients with an elevated result today is still "treat your other risks" — which we should be doing anyway.
“There are no trials suggesting that this strategy changes outcomes.”
John M. Mandrola · Electrophysiologist; Medscape · Medscape ↗
“A Class I recommendation for universal screening is a claim that testing everyone will lead to actions that make people healthier.”
“The vast majority of patients with ASCVD worldwide are being managed without knowledge of their Lp(a) levels even though over a quarter are at heightened risk because of their Lp(a). These findings underscore the need for major global educational efforts to promote Lp(a) measurem”
“If elevated Lp(a) levels are detected, they should work closely with their healthcare provider to aggressively lower LDL cholesterol and manage other cardiovascular risk factors as much as possible. This knowledge is especially valuable as new targeted treatment options are on th”
“elevated Lp(a) is an actionable entity today and failing to measure and respond to it represents a missed opportunity to prevent the first manifestations of life-altering ASCVD.”
“If you don’t measure it, if you don’t know how to treat it. I would argue that if you don’t know about your patients’ Lp(a), you also cannot define your primary prevention strategy.”
Vera A. Bittner · Professor of medicine and section head of General Cardiology · AJMC ↗
“While we don’t yet know if lowering Lp(a) translates to fewer cardiovascular events, we do know that identifying high-risk patients allows us to intervene earlier.”
“Elevated Lp(a) is inherited, causal, common, and meaningfully changes lifetime risk assessment. It can guide treatment intensity, helps identify family members at risk, and may inform trial eligibility.”
Michael D. Shapiro · Preventive cardiologist; 2026 ACC/AHA dyslipidemia guideline writing committee member · Medscape ↗
“we should not wait for lipoprotein(a)-lowering therapies, but rather start measuring now.”
Pia R. Kamstrup · Clinical biochemist and Lp(a) researcher · JACC: Case Reports ↗
“Clinicians must be aware of Lp(a) screening guidelines, recommended treatment options, and emerging pharmacotherapies targeting Lp(a) lowering that may soon be available.”
We can crush Lp(a) levels with new agents, but no trial has yet shown that doing so cuts events — treating before the data risks repeating past lipid surprises where surrogate wins didn't translate.
“Horizon study is a pivotal phase 3 study designed to test the hypothesis that treatment with monthly subcutaneous injection of pelacarsen 80 mg will significantly reduce the risk of major adverse cardiovascular events.”
“There are no approved pharmacological therapies to effectively lower Lp(a) for the more than eight million patients living with cardiovascular disease and elevated levels of Lp(a) worldwide.”
Sotirios Tsimikas · Senior Vice President · Ionis ↗
“There are no trials suggesting that this strategy changes outcomes. It’s fine to consider Lp(a), but it should come with a weaker recommendation such as Class IIb “may be considered.””
John M. Mandrola · Cardiac electrophysiologist · Medscape ↗
“We want clinicians to start assessing Lp(a) now so that when Lp(a)-targeted therapies become available, we’ll be ready to treat the patients who need them”
“The 2026 ACC/AHA dyslipidemia guideline gave a Class I recommendation for measuring lipoprotein(a) (also known as Lp(a)) at least once in every adult.”
James Stein · Preventive cardiologist · Substack ↗
“For those of us who practice preventive cardiology and lipidology, it can alter our clinical management.”
Serves as a principal site investigator for the pivotal HORIZON trial.
Estimated patients affected
0–0
Approximately 20% of the global population→Just 0.1% of adults in a contemporary cohort of 71 million individuals from the general population had ever undergone lipoprotein(a) (Lp(a)) testing
Black patients~3x higher Lp(a) than white, Hispanic or↗
Younger patientsHigher levels than older patients↗
Familial hypercholesterolemia40.7% have elevated Lp(a)↗
›How this is estimated
Prevalence: Approximately 20% of the global population source
Effect size: a 23% reduction with baseline Lp(a) above the median versus 7% below the median source
Practice gap: Just 0.1% of adults in a contemporary cohort of 71 million individuals from the general population had ever undergone lipoprotein(a) (Lp(a)) testing source
prevalence × practice gap, ±25% band
Some details are pending source verification and are withheld until confirmed.
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
“some recommendations may benefit from clarification to improve internal alignment. For example, the guideline includes Class 1 recommendations both for DAPT for 1 year (to reduce ischemic events) and for switching to ticagrelor monotherapy after 1 month of tolerating DAPT (to red”
“A paradigmatic example is the recommendation of the P2Y12 inhibitor of choice in ACS patients proceeding to PCI: the ESC guideline recommend prasugrel over ticagrelor based on the ISAR REACT 5 trial, whereas for the American guideline, both agents are equally recommended.”
“A paradigmatic example is the recommendation of the P2Y12 inhibitor of choice in ACS patients proceeding to PCI: the ESC guideline recommend prasugrel over ticagrelor based on the ISAR REACT 5 trial, whereas for the American guideline, both agents are equally recommended.”
“the 2025 guidelines for the management of acute coronary syndromes (ACS) are exhaustive and relatively all-inclusive, recent research has highlighted the presence of gray areas, controversies”
Merging STEMI and NSTEMI into one framework finally aligns practice with a decade of trials, and the flexibility clinicians read as 'conflict' is really room to individualize between ischemic and bleeding risk.
“By grouping STEMI and NSTEMI together, she added, “I’m really hoping that it’s going to make everybody much more comfortable because we had clinical trials that came out, but the guidelines were so out of date.””
Jacqueline E. Tamis-Holland · Cardiologist · TCTMD ↗
“intracoronary imaging is recommended to guide PCI in patients with ACS with complex coronary lesions”
“Use intracoronary imaging to guide percutaneous coronary intervention (PCI). This recommendation was not included in prior STEMI and NSTEMI guidelines... elevated to a class 1”
“The current guidelines rightly -- American and European -- remain cautious with the class 2b recommendations, reflecting a field where clinical enthusiasm has clearly outpaced high quality evidence.”
Practice gap: Current US estimates suggest that only 12% of NSTE-ACS patients receive all guideline-recommended therapies within the first 48 hours. source
Some details are pending source verification and are withheld until confirmed.
Who: Hemodynamically stable ACS without contraindication, first 24 hours·26 sources
On the board:since Jun 24, 2026 (2 mo)— time live on Synapse
Patients affected:Millions of patients· routine practice across all ACS care
›The evidence
What we know
✓The 2025 guideline unifies STEMI and NSTEMI into a single ACS framework.
✓It carries Class 1 recommendations for both a full year of dual antiplatelet therapy and for shortening or de-escalating it.
✓US and European guidelines diverge on the preferred P2Y12 inhibitor after PCI.
✓The document folds in a decade of accumulated antiplatelet, anticoagulation, and mechanical support evidence.
What's still unknown
?Which patients should get the full year of dual therapy versus early de-escalation.
?Whether prasugrel or ticagrelor is truly the better first choice in ACS going to PCI.
?How the internal Class 1 tensions should be resolved at the bedside.
?Whether the unified approach changes real-world outcomes versus separate STEMI/NSTEMI pathways.
Many of these new Class I recommendations rest on modeling and observational data rather than randomized outcome trials, so lowering the bar risks medicating large numbers of people who would never have had an event.
“Too many Class I recommendations lacking supporting data from randomized trials.”
John Mandrola · Cardiologist and Medscape commentator · Medscape ↗
Undecided
“It’s a big change, going from the Pooled Cohort Equations to PREVENT.”
“The guideline advances a new approach to risk assessment through a novel risk score, sets lower LDL-C goals, and recommends measuring Lp(a) at least once.”
“While we want to try to optimize healthy lifestyle habits as the first step to lower cholesterol, we realize that if lipid numbers aren't within the desirable range after a period of lifestyle optimization, we should consider adding lipid-lowering medication earlier than we would”
“The guideline addresses the evaluation, management, and monitoring of individuals with lipid disorders, including high blood cholesterol, hypertriglyceridemia, and elevated Lp(a).”
“The Guideline-at-a-Glance provides a visual overview of key concepts from the 2026 ACC/AHA Multisociety Dyslipidemia Guideline, highlighting major updates in risk assessment and treatment goals.”
“Given the enhanced accuracy of the PREVENT-ASCVD equations, which provide risk estimates that are approximately 40% to 50% lower than the PCE, the current guideline panel selected the 10-year estimated ASCVD risk threshold of ≥3% for beginning consideration of [lipid-lowering the”
“This is why we are emphasizing checking cholesterol at a young age — not because we want to start everybody on statins early, but because having high cholesterol for a long time makes it more likely that someone will have a heart attack or stroke.”
“It's still too early to be advocating treating every vulnerable plaque that you see, but it’s an interesting piece of data because we all commonly see high-risk features that we know predict future events, but we don’t know what we should do about them.”
Mamas A. Mamas · Keele University · TCTMD ↗Marc P. Bonaca · University of Colorado · TCTMD ↗
“Lack of a decades-long randomized controlled trial is not the same as a lack of evidence.”
Ann Marie Navar · Preventive cardiologist · Healio ↗
“There is indeed overwhelming evidence supporting our practice-changing Guideline.”
Roger Blumenthal · Preventive cardiologist · Medscape ↗
“Key updates to this guideline include: The use of the American Heart Association PREVENT-ASCVD equations to guide primary-prevention and lipid-lowering therapy decisions.”
AHA Science · American Heart Association Science account summarizing guideline authors · X @AHAScience ↗
“The main message is that not everyone needs a CAC scan and CAC zero should not be used as a veto against statin therapy.”
Michael Shapiro · Preventive cardiologist · STAT ↗
“We say try to achieve a 120 to 129 target in the first instance and you can opt out if the patient isn't tolerating that treatment or can't achieve that target.”
John William McEvoy · ESC hypertension guideline chair · TCTMD ↗
“There’s definitely less disparity now.”
Paul Whelton · U.S. hypertension guideline leader · TCTMD ↗James Stein · Preventive cardiologist · Medscape ↗
“Everybody's getting excited about them, but we must wait on the results. You don't know for sure until you see the data.”
Karol Watson · Preventive cardiologist · UCLA Health ↗
“Nearly a quarter of the world's population has elevated levels of [lipoprotein(a)], putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes.”
“This change is driven by new trial evidence confirming that more intensive BP treatment targets reduce CVD outcomes across a broad spectrum of eligible patients.”
“By addressing individual risks earlier and offering more tailored strategies across the lifespan, the 2025 guideline aims to aid clinicians in helping more people manage their blood pressure.”
Daniel Jones · 2025 BP guideline writing committee chair · MedPage Today ↗
“Of the 53 class one recommendations, only 10 or 22% were backed by randomized controlled trials.”
“Taken together, these studies show that the absence of CAC does not neutralize the long-term risk associated with sustained exposure to elevated LDL-C.”
James H. Stein · Preventive cardiologist · Substack ↗
“If it's high, we would treat your LDL very aggressively.”
Leslie Cho · Cleveland Clinic; guideline co-author · New York Times ↗Pamela B. Morris · Vice chair · HCPLive ↗Ann Marie Navar · 2026 dyslipidemia writing committee member · HCPLive ↗Roger Blumenthal · 2026 dyslipidemia guideline chair · TCTMD ↗
“Given the enhanced accuracy of the PREVENT-ASCVD equations, which provide risk estimates that are approximately 40% to 50% lower than the PCE, the current guideline panel selected the 10-year estimated ASCVD risk threshold of ≥3% for beginning consideration of [lipid-lowering”
“But I do not support this recommendation and did not support it even before the recent Lp(a)HORIZON topline results were reported as negative for the clinical benefit of lowering Lp(a) with pelacarsen.”
James H. Stein · Preventive cardiologist · Substack ↗
“In general, lower LDL is better, especially for people at increased risk for a heart attack or stroke.”
“The findings from the REDUCE-AMI trial provide important insights into the management of patients with AMI who have preserved LVEF of 50% or higher. The results underscore the importance of a more tailored approach to post-AMI management and may prompt a re-evaluation of existing”
“This study demonstrated in a more definitive fashion than the ABYSS study that yes, at 1 year, it is safe in patients with normal ejection fraction and no atrial fibrillation to stop that beta-blocker.”
“In appropriately selected patients who survived a heart attack and do not have [HF] or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary.”
The trials are noninferiority studies with soft margins and conflicting results, so pulling a cheap, proven drug from a patient who is doing fine risks trading certainty for a small unproven upside.
“Although it might be tempting to conclude that interruption of β-blocker in stabilized patients post-MI yields an unfavorable benefit-risk balance, a more nuanced interpretation would be that interruption did not increase the risk of bias-resistant outcomes of death, MI or stroke”
“For patients with myocardial infarction with LVEF of 50%, or higher beta-blockers are being reconsidered. While the REDUCE-AMI trial did not demonstrate benefit, there are additional trials underway and guideline recommendations have not yet been revised.”
“This is not definitive. Ours is only the first trial to demonstrate the safety of discontinuing beta-blockers in stable post-MI patients. We need more evidence.”
40 studies (1,527,848 patients) provide low-certainty evidence for benefit of beta-blockers for Myocardial Infarction Hospitalization in Myocardial Infarction.
Supporting
+Guideline concordant prescribing following myocardial infarction in people who are frail: A systematic review
+Adherence to secondary preventive treatment following myocardial infarction with and without obstructive coronary artery disease
+Advanced Stress Echocardiography with Cardiopulmonary Exercise Testing After Myocardial Infarction
+Association of Beta-Blocker Treatment with Mortality Following Myocardial Infarction in Patients with Chronic Obstructive Pulmonary Disease and Heart Failure or Left Ventricular Dysfunction: A Propensity Matched-Cohort Analysis from the High-Risk Myocardial Infarction Database Initiative
“The study largely confirms what a lot of people in the PE world have suspected, which is that the use of catheter-based interventions, including catheter-based thrombolysis, improves patient outcomes.”
“This trial shows that a catheter intervention can indeed be effective and improve the prognosis for patients with severe PE and elevated risk of early death or life-threatening complications.”
Stavros V. Konstantinides · HI-PEITHO lead author · ACC ↗
Anticoagulate first
Most intermediate-risk patients do fine on blood thinners alone, so adding a procedure exposes them to bleeding and cost for a benefit that may only exist in a narrow sicker subset.
“For the majority of patients with intermediate-risk PE, anticoagulation remains the right treatment. For the narrow subset with objective evidence of RV strain, positive troponin, and clinical signs of physiologic stress, CDT now has RCT evidence supporting its use.”
“CDT should be considered for patients with high-risk PE, in whom thrombolysis is contraindicated or has failed. Also, CDT is a treatment option for initially stable patients in whom anticoagulant treatment fails.”
Piotr Pruszczyk · ESC Working Group on Pulmonary Circulation · EuroIntervention ↗
Undecided
“This guideline is a road map to help clinicians navigate these advances for the safest and most effective approaches to care for people with this condition.”
“The wisdom of applying this approach to patients with less severe intermediate-risk PE remains unclear and will benefit from additional studies.”
Alex C. Spyropoulos · Editorialist · ACC ↗Wissam A. Jaber · PEERLESS investigator · Circulation ↗Kenneth Rosenfield · HI-PEITHO investigator · NEJM ↗
“At 30 days, a primary outcome event... was 61% lower in the catheter-directed therapy plus anticoagulation group compared with the anticoagulation-only group.”
“In contrast to interventions for myocardial infarction or stroke, there have been very few advances in the treatment of pulmonary embolism over the last 20 years. This has led to a considerable unmet clinical need that we can’t ignore.”
Viktor Kočka · PRAGUE-26 lead; Charles University Prague · Medical Dialogues ↗
“There was no significant difference in death, recurrent PE, or even 6-minute walk at 30 days, which indicates functional status.”
Alexandre Almorad · Brussels University Hospital · MedTech Dive ↗
“I was wrong to be skeptical of PFA.”
John Mandrola · Electrophysiologist using PFA · Medscape ↗
Stick with RF
If PFA isn't more effective and carries an unsettled stroke signal, there's no reason to abandon a cheaper, well-understood technology with decades of track record.
“PFA is here to stay, but the significant increase in the relative stroke risk with PFA should renew our commitment to rigorous post-market surveillance.”
“Other trials have compared PFA with thermal energy sources with inconclusive results. We conducted the BEAT-PAROX-AF trial to directly compare PFA with advanced RFA in patients with antiarrhythmic drug-resistant symptomatic paroxysmal AF.”
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
“This endorsement is likely to raise debate because P2Y12 inhibitor monotherapy trials have been criticized for design heterogeneity, a predominant focus on bleeding, and noninferiority frameworks for ischemic outcomes.”
“We failed to demonstrate the noninferiority of aspirin-free monotherapy initiated immediately after PCI with regard to the ischemic primary endpoint over 12 months.”
Pedro Lemos · NEO-MINDSET PI · ACC ↗Sanjay Kaul · Cedars-Sinai · JACC ↗
“Dual antiplatelet therapy with aspirin and an oral P2Y12 inhibitor is indicated for at least 12 months as the default strategy in patients with ACS who are not at high bleeding risk.”
“The body of data over the past five-to-eight years is compelling and strongly supports consideration of complete revascularization in patients with ACS”
Named experts we found publicly on record — a sample, not a representative poll of the field.
1Drop aspirin at one month10unplaced4Twelve months stays the default
Named experts on the record — a snapshot from the scan, not a poll. The measured clinician split builds below.
Where do you land?
No votes yet — the measured split appears at 10.
Estimated patients affected
680K–1.1M
Around 900,000 PCIs are performed every year in the U.S.→Dual antiplatelet therapy for 12 months is the current standard of care in patients with acute coronary syndrome (ACS).
Who: STEMI or NSTE-ACS with multivessel disease, hemodynamically stable vs in shock·42 sources
On the board:since Jun 23, 2026 (2 mo)— time live on Synapse
Patients affected:Millions of patients· routine decision after every heart attack stent
›The evidence
What we know
✓Aspirin plus a potent P2Y12 blocker for a year prevents clots but reliably causes more bleeding.
✓In the ticagrelor-monotherapy trials, stopping aspirin early cut bleeding without an obvious rise in ischemic events.
✓US and European guidelines now disagree: the 2025 ACC/AHA guideline calls early ticagrelor monotherapy a strong recommendation, while ESC is more cautious and waits three to six months.
✓Bleeding after stenting is not benign — it tracks with worse survival, which is why shortening therapy is attractive at all.
What's still unknown
?Whether the results hold in patients underrepresented in the trials: STEMI, left main, bifurcations, long multivessel stenting.
?Whether the largely East Asian trial populations translate to Western patients with different bleeding and clotting profiles.
?Whether prasugrel alone works the same way — it has essentially not been tested as monotherapy.
?Whether one month is truly the right cut point, or whether three months is the safer floor for higher ischemic risk.
“In my opinion, applying the same criteria used with symptomatic patients is beneficial for patients, meaning that, in patients with low-to moderate surgical risk, if we accept the results of TAVI trials, the transcatheter option is entirely acceptable.”
José Antonio Baz Alonso, MD · Interventional cardiologist · REC Interv Cardiol ↗
“These trial data are the first suggesting consideration of TAVI in asymptomatic severe AS is indicated before the onset of clinical decline associated with progression of valvular dysfunction.”
The trials leaned on soft endpoints, skipped a surgery comparison arm, and we still don't know how these valves hold up over decades — so committing a symptom-free patient to a valve is premature.
“The EARLY TAVR trial does not establish a meaningful patient-centered benefit for asymptomatic Medicare beneficiaries”
NCHR · National Center for Health Research · NCHR ↗
“There was hope among some members of the community that we would come up with a level I recommendation for asymptomatic aortic stenosis, and we just didn’t feel that the evidence was clear enough.”
“The endpoint choice and the omission of a SAVR arm means the trial doesn’t fully inform the decision regarding the timing of aortic valve intervention in patients with asymptomatic but severe AS.”
John M. Mandrola, MD · Cardiac electrophysiologist · Medscape ↗
Undecided
“An asymptomatic person is really hard to make much better. If the patient is not complaining of anything, I think the evidentiary bar has to be quite high.”
John M. Mandrola · Electrophysiologist · Medscape ↗
“I don't think we can say this is a level 1 recommendation. I think level 1 is a bridge too far.”
David J. Cohen · Director of clinical and outcomes research · Medscape ↗
“The endpoint choice and the omission of a SAVR arm means the trial doesn’t fully inform the decision regarding the timing of aortic valve intervention in patients with asymptomatic but severe AS.”
John M. Mandrola · Electrophysiologist; Medscape commentator · Medscape ↗
“this recommendation clearly opens the door for early treatment in, I think, a balanced and nice way.”
“Given the benefits observed and the lack of harm, early TAVR may be preferred to CS in patients with asymptomatic severe AS, especially when combined with the challenges of timely symptom recognition and prompt treatment in real-world settings.”
“Its results strongly favored TAVR, but two glaring design flaws remove nearly all its clinical value.”
John Mandrola · Electrophysiologist / commentator · Medscape ↗
“We shouldn’t rely on the development of what are cited as class II recommendations to make a treatment decision.”
Patrick O'Gara · Brigham and Women's Hospital · TCTMD ↗
“These findings provide a strong rationale for prompt intervention in patients with asymptomatic severe aortic stenosis at least to prevent progression to acute valve syndrome and poor outcome.”
“They called it a conversion when those clinical surveillance patients went on to undergo TAVR due to symptoms, but that should have been viewed as a crossover.”
“Registry study showed 50% increase in mortality at 3y with delayed TAVR, but mortality was not increased in EARLY-TAVR at median f/u of 3.8y (HR 0.93, 0.60-1.44). Should we chase potentially confounded data to justify early TAVR?”
“There's a lot to worry about in the exuberance to intervene on people-with-no-complaints, not least because even the diagnosis of severe AS is not always correct.”
John Mandrola · Electrophysiologist; Medscape · Medscape ↗
“It seems that there is no advantage in waiting.”
Philippe Généreux · EARLY TAVR PI · SECCE ↗John M. Mandrola · Electrophysiologist / trial critic · Medscape ↗
“Among patients with asymptomatic severe aortic stenosis, a strategy of early TAVR was superior to guideline-recommended clinical surveillance in reducing the composite end point of death, stroke, or unplanned hospitalization for cardiovascular causes.”
Philippe Généreux · EARLY TAVR investigator · NEJM ↗
“I personally think this will be a fairly nuanced conversation with the patient.”
“The totality of the evidence does not support endorsing early AVR, especially TAVR, as the preferred therapy for low-risk patients with asymptomatic severe AS.”
“Expanding early or preemptive interventional treatment to all asymptomatic patients who might formally meet hemodynamic and anatomical criteria may be premature. For now, awaiting symptoms remains a justifiable strategy.”
Stefan Blankenberg · University Heart & Vascular Center Hamburg · TCTMD ↗
“Even at 6 months, one in four patients has symptoms and conversion to treatment.”
Anna Sonia Petronio · Pisa University Hospital; structural cardiologist · TCTMD ↗
“The EARLY TAVR trial does support early intervention as the preferred strategy, independent of guideline indications.”
Allan Schwartz · Columbia University Irving Medical Center · Cardiovascular News ↗Philippe Généreux · EARLY TAVR PI; Morristown Medical Center · ACC ↗
“I think the message is, as soon as a patient has severe aortic stenosis, they should be referred. And we should treat the patient as soon as possible.”
“Expanding early or preemptive interventional treatment to all asymptomatic patients who might formally meet hemodynamic and anatomical criteria may be premature.”
“Antiplatelet and anticoagulation trials like NEO-MINDSET, TARGET FIRST, DUAL-ACS test earlier withdrawal of aspirin or oral anticoagulants to reduce bleeding risk.”
“Abbreviation of DAPT duration after 1–6 months, followed by monotherapy with aspirin or a P2Y12 inhibitor, reduces bleeding without an increase in ischaemic events in patients at high bleeding risk, particularly those without high ischaemic risk.”
“Recent evidence suggests that withdrawal of aspirin after 1 to 3 months of DAPT, followed by P2Y12 inhibitor monotherapy may reduce bleeding while preventing recurrent ischaemic events compared with 12 months of DAPT.”
“No previous randomized trials have assessed early aspirin discontinuation in acute MI patients who achieve early, complete revascularization with modern stents.”
“This all-comer real-world trial recruited only 30% of the planned participants and was unable to address the primary question definitively. However, there was no evidence that DAPT given for 12 months conferred any additional benefit.”
Until adequately powered trials pin down exactly who can safely drop aspirin, abandoning the guideline-recommended 12 months risks recurrent thrombosis in patients who still need protection.
“In high-risk PCI patients, further ischemic events remain a life-threatening concern. As seen in TWILIGHT, in patients who tolerated three months of dual antiplatelet therapy, lowering the risk of major bleeding while preserving the ischemic benefit using ticagrelor monotherapy i”
“Until adequately powered randomised controlled trials demonstrate a clinically meaningful identification of those patients, we should continue to adhere to the current guideline-recommended 12-month minimum DAPT duration following ACS.”
“We failed to demonstrate the noninferiority of aspirin-free monotherapy initiated immediately after PCI with regard to the ischemic primary endpoint over 12 months.”
“Overall, these findings suggest that in acute coronary syndrome patients undergoing PCI, very early aspirin withdrawal does not reduce early bleeding and significantly increases ischemic events at 30 days.”
“In the absence of demonstrable benefit, and certain signals of harm that are consistent with prior data, really we should be giving patients three months of antiplatelet therapy after a heart attack and not 12 months.”
“Beta blocker therapy is one of the areas where there continues to be additional clinical trials that have been released since the finalization of the 2025 document.”
“Immediate P2Y12 inhibitor monotherapy with withdrawal of aspirin is not as protective as DAPT for ischemic events in patients with ACS after PCI, even though it does reduce bleeding.”
Pedro A. Lemos · NEO-MINDSET investigator · Healio ↗
“In low-risk patients, and not only in high-bleeding-risk patients, an aspirin-free strategy is possible after 1-month DAPT.”
“Among patients who had undergone successful PCI for acute coronary syndromes, potent P2Y12 inhibitor monotherapy was not found to be noninferior to dual antiplatelet therapy with respect to a composite of death or ischemic events at 12 months.”
Pedro A. Lemos · NEO-MINDSET investigator · NEJM ↗
Named experts we found publicly on record — a sample, not a representative poll of the field.
7De-escalate early9unplaced4Hold the line
Named experts on the record — a snapshot from the scan, not a poll. The measured clinician split builds below.
Where do you land?
No votes yet — the measured split appears at 10.
Estimated patients affected
450K–750K
>600,000 patients undergo PCI annually in the US, majority for ACS
6 studies (71,537 patients) provide insufficient evidence with mixed findings regarding aspirin for the outcome in Acute Coronary Syndrome.
Supporting
+Optimal timing of aspirin discontinuation after acute coronary syndrome treated with percutaneous coronary intervention: a systematic review and meta-analysis
Dissenting
−Preoperative dual antiplatelet therapy increases risk after urgent coronary bypass surgery: A Netherlands heart registration study
−Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy
−P2Y12 inhibitor monotherapy after abbreviated dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
Biykem Bozkurt · Discussant; Baylor College of Medicine · TCTMD ↗
“There is already convincing evidence that when patients are hospitalized with HF, all four pillars of guideline-directed medical therapy (GDMT)—including SGLT2 inhibitors—should be started.”
Filippo Crea · Moderator; Catholic University · TCTMD ↗
“Based on these results and on the early appearance of their beneficial effects, the administration of SGLT2 inhibitors should start early in patients hospitalized for acute HF.”
“Early initiation of SGLT2i in patients with acute HF did not increase the risk of any of the following endpoints compared to the control group... Its early implementation reduces the risk of HF hospitalizations and AKI.”
An acutely congested patient with shifting kidney function and volume status may not tolerate a new agent well, and the early outcome edge over a prompt outpatient start hasn't been clearly shown.
“Therefore, early initiation should not be generalized to all patients with AHF. Instead, SGLT2 inhibitors should be started after careful assessment of haemodynamic stability, renal function, volume status, infection risk, and metabolic status.”
“We took 240 patients across six hospital sites in the US, randomized them within 24 hours of presenting to the hospital, to either starting dapagliflozin 10 mg daily or structured usual care.”
“We designed the DIGIT-HF trial with digitoxin – which has stable blood concentrations even in patients with renal dysfunction – and included patients with HF and a pronounced HF symptom burden.”
“Insufficient evidence exist to date to confidently conclude that semaglutide and tirzepatide reduce HF events in individuals with HFpEF and obesity (with stronger evidence for tirzepatide)”
Michelle M. Kittleson · ACC scientific statement lead author · JACC ↗Scott Solomon · Brigham and Women's Hospital; HF trialist · JACC ↗
“If they are obese with comorbidities, you have the GLP-1-based therapies.”
“If you approach SUMMIT from the view of a regulator, with its small numbers of outcome events and bias-susceptible endpoints, you cannot allow a disease-modifying claim.”
John M. Mandrola · Electrophysiologist · Medscape ↗
Named experts we found publicly on record — a sample, not a representative poll of the field.
9Start before discharge8unplaced1Stabilize first
Named experts on the record — a snapshot from the scan, not a poll. The measured clinician split builds below.
Where do you land?
No votes yet — the measured split appears at 10.
Estimated patients affected
75K–120K
Over 1 million US hospitalizations annually→Often below 10% in eligible hospitalized patients
›How this is estimated
Prevalence: Over 1 million US hospitalizations annually source
Effect size: 28% relative risk reduction in all-cause mortality source
Practice gap: Often below 10% in eligible hospitalized patients source
prevalence × practice gap, ±25% band
Some details are pending source verification and are withheld until confirmed.
4 studies (289 patients) provide low-certainty evidence for benefit of SGLT2 inhibitors for the outcome in Patients with heart failure (HFrEF and HFpEF) and preclinical/translational models.
Beta-blockers after myocardial infarction with preserved ejection fraction: A meta-analysis with trial sequential analysis
Dissenting
−Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark
−Long-term beta blocker prescribing after myocardial infarction in European primary care (PRACTITIONER).
−Difference in Medication Adherence Between Patients Prescribed a 30‐Day Versus 90‐Day Supply After Acute Myocardial Infarction
−Factors associated with low-density lipoprotein control in outpatients with myocardial infarction: A hospital-based study
−Pharmacological treatment after a first myocardial infarction in Sweden—long-term adherence and prognosis
A shorter duration of dual-antiplatelet therapy for percutaneous coronary intervention following acute coronary syndrome: a meta-analysis of randomized clinical trials